Abstract
The delivery of large hydrophilic molecules (i.e., peptides and proteins) across biological barriers has been hampered by the presence of tight junctions. This delivery process can be improved by enhancing permeation through intercellular junctions of the intestinal mucosa and blood-brain barriers. This is achieved by modulating the intercellular junctions of these biological barriers. To modulate intercellular junctions, it is necessary to understand the structure and function of the proteins that are involved in these junctions. This review focuses on the structure of intercellular junctions and possible mechanisms of intercellular junction formation. Modulation of protein-protein interactions has been shown to increase the porosity of the paracellular pathway. For example, E-cadherin derived peptides have been shown to enhance the permeation of hydrophilic molecules (i.e., mannitol) in cell culture models of biological barriers.
Keywords: Blood-brain barrier, claudin, drug delivery, E-cadherin, intestinal mucosa, JAM, paracellular permeation, tight junctions
Current Pharmaceutical Design
Title: Structure and Function of the Intercellular Junctions: Barrier of Paracellular Drug Delivery
Volume: 12 Issue: 22
Author(s): Kai Zheng, Maulik Trivedi and Teruna J. Siahaan
Affiliation:
Keywords: Blood-brain barrier, claudin, drug delivery, E-cadherin, intestinal mucosa, JAM, paracellular permeation, tight junctions
Abstract: The delivery of large hydrophilic molecules (i.e., peptides and proteins) across biological barriers has been hampered by the presence of tight junctions. This delivery process can be improved by enhancing permeation through intercellular junctions of the intestinal mucosa and blood-brain barriers. This is achieved by modulating the intercellular junctions of these biological barriers. To modulate intercellular junctions, it is necessary to understand the structure and function of the proteins that are involved in these junctions. This review focuses on the structure of intercellular junctions and possible mechanisms of intercellular junction formation. Modulation of protein-protein interactions has been shown to increase the porosity of the paracellular pathway. For example, E-cadherin derived peptides have been shown to enhance the permeation of hydrophilic molecules (i.e., mannitol) in cell culture models of biological barriers.
Export Options
About this article
Cite this article as:
Zheng Kai, Trivedi Maulik and Siahaan J. Teruna, Structure and Function of the Intercellular Junctions: Barrier of Paracellular Drug Delivery, Current Pharmaceutical Design 2006; 12 (22) . https://dx.doi.org/10.2174/138161206777947722
DOI https://dx.doi.org/10.2174/138161206777947722 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiviral Activity of Jodantipyrin – An Anti-Inflammatory Oral Therapeutic with Interferon-Inducing Properties
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Endothelin Axis: A Novel Target for Pharmacotherapy of Female Malignancies
Current Vascular Pharmacology Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry Dual-acting of Hybrid Compounds - A New Dawn in the Discovery of Multi-target Drugs: Lead Generation Approaches
Current Topics in Medicinal Chemistry Expression and Clinical Significance of Microtubule-Actin Cross-Linking Factor 1 in Serous Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Emerging Immunotargets in Bladder Cancer
Current Drug Targets Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology Seeds of Mung Bean (<i>Vigna radiata</i> (L.) R.Wilczek): Taxonomy, Phytochemistry, Medicinal Uses and Pharmacology
Current Bioactive Compounds The Acute Phase Protein α1-Acid Glycoprotein: A Model for Altered Glycosylation During Diseases
Current Protein & Peptide Science Pharmacogenetics and Anaesthesiology
Current Pharmacogenomics Targeting Myc in Pediatric Malignancies of the Central and Peripheral Nervous System
Current Cancer Drug Targets The SCF-type E3 Ubiquitin Ligases as Cancer Targets
Current Cancer Drug Targets Orthotopic Liver Transplantation in Non-Alcoholic Fatty Liver Disease Patients
Reviews on Recent Clinical Trials Aerosol Delivery in the Treatment of Lung Cancer
Current Cancer Drug Targets Targeting the Resistance of Pancreatic Cancer Cells to Nutrient Deprivation: Anti-Austerity Compounds
Current Drug Delivery The Role of the Adenosinergic Pathway in Immunosuppression Mediated by Human Regulatory T Cells (Treg)
Current Medicinal Chemistry Current Trends in the Chemotherapy of Colorectal Cancer
Current Medicinal Chemistry Receptor Tyrosine Kinase Kit and Gastrointestinal Stromal Tumours: An Overview
Current Medicinal Chemistry 2-(ω-Carboxyethyl)pyrrole Antibody as a New Inhibitor of Tumor Angiogenesis and Growth
Anti-Cancer Agents in Medicinal Chemistry Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets
Current Enzyme Inhibition